CN118043343A - 经修饰的白细胞介素p40亚基蛋白质及其使用方法 - Google Patents

经修饰的白细胞介素p40亚基蛋白质及其使用方法 Download PDF

Info

Publication number
CN118043343A
CN118043343A CN202280063447.6A CN202280063447A CN118043343A CN 118043343 A CN118043343 A CN 118043343A CN 202280063447 A CN202280063447 A CN 202280063447A CN 118043343 A CN118043343 A CN 118043343A
Authority
CN
China
Prior art keywords
domain
amino acid
modified
fusion protein
fold
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280063447.6A
Other languages
English (en)
Chinese (zh)
Inventor
R·布莱克勒
T·斯普雷特·冯克罗登斯泰恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Enzymatic British Columbia Ltd
Original Assignee
Enzymatic British Columbia Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Enzymatic British Columbia Ltd filed Critical Enzymatic British Columbia Ltd
Publication of CN118043343A publication Critical patent/CN118043343A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50—Mutagenesis
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B35/00—ICT specially adapted for in silico combinatorial libraries of nucleic acids, proteins or peptides
    • G16B35/10—Design of libraries

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN202280063447.6A 2021-09-29 2022-09-29 经修饰的白细胞介素p40亚基蛋白质及其使用方法 Pending CN118043343A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163249685P 2021-09-29 2021-09-29
US63/249,685 2021-09-29
PCT/CA2022/051445 WO2023050006A1 (en) 2021-09-29 2022-09-29 Modified interleukin p40 subunit proteins and methods of use thereof

Publications (1)

Publication Number Publication Date
CN118043343A true CN118043343A (zh) 2024-05-14

Family

ID=85780291

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280063447.6A Pending CN118043343A (zh) 2021-09-29 2022-09-29 经修饰的白细胞介素p40亚基蛋白质及其使用方法

Country Status (9)

Country Link
US (1) US20240228567A1 (enExample)
EP (1) EP4408870A4 (enExample)
JP (1) JP2024535925A (enExample)
KR (1) KR20240068070A (enExample)
CN (1) CN118043343A (enExample)
AU (1) AU2022355496A1 (enExample)
CA (1) CA3232071A1 (enExample)
MX (1) MX2024003940A (enExample)
WO (1) WO2023050006A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200089312A (ko) 2017-11-28 2020-07-24 추가이 세이야쿠 가부시키가이샤 리간드 결합 활성을 조정 가능한 리간드 결합 분자
EP3981428A4 (en) 2019-06-05 2023-07-12 Chugai Seiyaku Kabushiki Kaisha Protease substrate, and polypeptide including protease cleavage sequence
CN115943210A (zh) 2020-01-20 2023-04-07 中外制药株式会社 配体结合融合蛋白
AU2024407051A1 (en) 2023-12-18 2026-07-30 Genzyme Corporation Il-12 loss of potency muteins
WO2025151752A1 (en) 2024-01-10 2025-07-17 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof
WO2026020161A1 (en) 2024-07-19 2026-01-22 Cytomx Therapeutics, Inc. Activatable il-12 constructs and related compositions and methods

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102884523B1 (ko) * 2018-10-03 2025-11-10 젠코어 인코포레이티드 IL-12 이종이량체 Fc-융합 단백질
MX2022011676A (es) * 2020-03-23 2023-03-08 Zymeworks Bc Inc Proteinas de fusion de il12 con enmascaramiento y metodos para su uso.

Also Published As

Publication number Publication date
EP4408870A4 (en) 2025-10-22
EP4408870A1 (en) 2024-08-07
US20240228567A1 (en) 2024-07-11
KR20240068070A (ko) 2024-05-17
MX2024003940A (es) 2024-04-22
JP2024535925A (ja) 2024-10-02
CA3232071A1 (en) 2023-04-06
AU2022355496A1 (en) 2024-05-02
WO2023050006A1 (en) 2023-04-06

Similar Documents

Publication Publication Date Title
JP7773991B2 (ja) マスクされたｉｌ１２融合タンパク質及びその使用方法
US20240228567A1 (en) Modified interleukin p40 subunit proteins and methods of use thereof
US20240043535A1 (en) IMMUNE ACTIVATING Fc DOMAIN BINDING MOLECULES
US20230227584A1 (en) Bispecific antibodies comprising a modified c-terminal crossfab fragment
CN112424228B (zh) 新型双特异性激动性4-1bb抗原结合分子
CN113677403B (zh) 包含脂质运载蛋白突变蛋白的双特异性抗原结合分子
CN105017429B (zh) 多聚体il-15可溶性融合分子与其制造与使用方法
JP2021522175A (ja) Ｉｌ−１５／ｉｌ−１５ｒａヘテロ二量体ｆｃ融合タンパク質およびその使用
TW201806972A (zh) 雙特異性結合蛋白
CN106062206A (zh) 双特异性cd3和cd19抗原结合构建体
JP2023509952A (ja) 新規４－１ｂｂｌ三量体含有抗原結合分子
KR20240046224A (ko) 이중특이성 항체 및 그 용도
WO2024039973A2 (en) Masking polypeptide, activatable novel prodrugs and methods of use thereof
WO2025133042A2 (en) Activatable fusion proteins and methods of use
HK40110021A (en) Modified interleukin p40 subunit proteins and methods of use thereof
HK40085919A (en) Masked il12 fusion proteins and methods of use thereof
HK40091599A (en) Immune activating fc domain binding molecules
KR20260030113A (ko) 항체 및 그의 용도
WO2025036892A1 (en) Cycat halfbody molecules comprising sterically occluding moieties
HK40119034A (en) Interferon gamma variants and antigen binding molecules comprising these
CN119095880A (zh) 干扰素γ变体以及包含这些变体的抗原结合分子
CN116997362A (zh) 含调节免疫细胞功能的cd8抗原结合分子的融合物
HK40075193A (en) Bispecific antibodies comprising a modified c-terminal crossfab fragment
HK1190729A (en) Multimeric il-15 soluble fusion molecules and methods of making and using same
HK1190729B (en) Multimeric il-15 soluble fusion molecules and methods of making and using same

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40110021

Country of ref document: HK